Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory Panel Backs Approval Of Auxilium's Xiaflex, Wants Post-Market Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Members agree 12-0 that drug is approvable, offer opinion on who should dispense and the amount of training needed.

You may also be interested in...



Financings Of The Fortnight: IPOs Make A Return In Talecris And Omeros Deals

Money continued to flow to big and small biotechs, including nearly a dozen PIPEs or registered direct offerings.

Financings Of The Fortnight: IPOs Make A Return In Talecris And Omeros Deals

Money continued to flow to big and small biotechs, including nearly a dozen PIPEs or registered direct offerings.

Auxilium Xiaflex's Advisory Committee To Focus On Physician Expertise, Training

Majority of clinical trial investigators were hand or orthopedic surgeons and FDA asks if this level of expertise is needed to safely use the biologic.

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel